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INTRODUCTION
metabolites in man to parameterize a PK model and estimate the human dose required to achieve the target 'parent equivalents' exposure.
Model Structure
A system of differential equations was constructed in Berkeley Madonna (version 8.3 .18, Berkeley Madonna Inc., University of California, Berkeley, CA) to represent the flux through the proposed metabolic pathways (Figure 1) . A schematic of the model structure is presented in Figure 2 and the full model code is available (Supplemental Material 1). An overview of the generation of the model inputs is given below and these are summarized, together with their numerical values, in Table 1 . Readers can execute the model code by copying and pasting from the supplemental material directly into a blank Berkeley Madonna equations page. Furthermore, the approach and model are generally applicable and the reader may transpose them to their own active metabolite scenario by consideration of Figure 2 , creation of the appropriate model structure, and subsequent editing of the model code.
Overview of generation of model input data.
All animal studies were performed using protocols approved by the Merck Institutional Animal Care and Use Committee.
The putative metabolic pathway of MRK-1, M1 and M2 was elucidated by high resolution mass spectrometry and LC-MS/MS analysis of incubates generated in microsomes and hepatocytes (rat, dog, human) and recombinant human CYPs as well as of plasma from PK studies (rat, dog).
The primary in vitro potencies of MRK-1, M1 and M2 at the pharmacological target were determined by immobilized metal ion affinity-based fluorescence polarization using the phosphorylated active human enzyme. The in vivo efficacy of MRK-1 was assessed in a mouse xenograft model in which human-derived tumor cells were implanted into the flank of female CD1 nude mice. Following a 3 week tumor establishing period, MRK-1 was administered as a Blood samples were centrifuged to yield plasma which was then analyzed by LC-MS/MS to quantify MRK-1, M1 and M2. Tumors were measured using calipers and tumor volume was calculated according to the algorithm: Volume = ½(Length x Width 2 ). The efficacious dose was considered to be the minimum dose level that elicited tumor regression over the time course of the study.
The in vitro intrinsic clearances of MRK-1, M1 and M2 were determined in cryopreserved rat, dog and human hepatocytes using a standard substrate depletion method (eg: Naritomi et al., 2003) and quantified via LC-MS/MS. Compounds were incubated for 120 min at 0.3 µM in Krebs- nitrogen flow values for nebulizer gas (Gas 1), auxiliary gas (Gas 2), curtain gas and the gas for . The lack of conversion of M1 to M2 in dog hepatocytes was consistent with known Nacetylation species differences (Tibbits, 2003; Gao et al., 2006; Loureiro et al., 2013) . Further qualification of the PK model using rat data would therefore clearly have been desirable; however the metabolism of M1 to M2 observed in rat blood, but not dog or human blood, rendered such a validation questionable both in terms of feasibility and value. Since the in vivo efficacy model was only available in the mouse, it was not possible to validate the dose prediction in another species.
However, since such a model would employ human tumor cells lines in common with the mouse model, it would perhaps not be a true test of translatability. A further assumption of the model was that free plasma concentrations of MRK-1, M1 and M2 were a surrogate for the efficacious intratumoral concentrations. In vitro studies into the potential for active transport were inconclusive (data not shown) and no data were available on the expression of drug transporters in the tumor cell line. Therefore the relationship between plasma and tumor free drug levels is unknown but would be an area of focus for a more mechanistic understanding of the system. Despite these limitations, based on the partial qualification using dog data, and with the assumption that hepatic metabolism is the major clearance pathway for MRK-1, M1 and M2, the metabolic pathway fractionation approach and the model were deemed to be fit for purpose in a drug discovery setting.
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This article has not been copyedited and formatted. The final version may differ from this version. For MRK-1, the predicted efficacious dose of 187 mg, once daily, was deemed to be feasible for further development with sufficient margin for error. As in the dog, the prediction accuracy may have been affected by issues such as inaccuracies in the estimation of formation rate intrinsic clearances and clearance by non-hepatic metabolic mechanisms. In addition, the model did not take into account the possibility of first pass extraction of MRK-1 by the gut and this is a potential area for future work to strengthen the model. The model predicted that the majority of the clinical efficacy would be driven by metabolite M1 and, as such, MRK-1 may be thought of as a prodrug even though it is active in its own right. M2 was predicted to contribute only 3% of the efficacious exposure equivalents, consistent with its relatively low fractional formation (0.02 from MRK-1 and 0.08 from M1; Table 1 ) and subsequent metabolism back to M1. The predicted elimination rate constants (Table 1) suggest that the half-life of M1 would be approximately 10 h in man, compared to 5.5 h for MRK-1, yielding a combined profile more suited to once daily administration than for MRK-1 without active metabolites. Conversion to the active metabolite M1 may therefore be deemed to be a very beneficial feature of MRK-1, both in terms of required dose size and administration frequency In the model, either turning off the conversion of MRK-1 to M1, or making M1 pharmacologically inactive, both yielded a predicted human efficacious dose of approximately 800 mg MRK-1 daily, which is much less feasible from a formulation and development perspective. In this scenario, the predicted peak concentrations of MRK-1 are some four to five-fold higher, with the potential for a greater safety risk. To ameliorate these issues, it is likely that MRK-1, without its active metabolite, would be a b.i.d. drug.
In conclusion, the modeling approach described here facilitated a pragmatic prediction of the This article has not been copyedited and formatted. The final version may differ from this version. 
